These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10969062)

  • 21. Determining the value of antimicrobial surveillance programs.
    Jones RN; Masterton R
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):171-5. PubMed ID: 11777655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes.
    Unemo M; Fasth O; Fredlund H; Limnios A; Tapsall J
    J Antimicrob Chemother; 2009 Jun; 63(6):1142-51. PubMed ID: 19318360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).
    Jones RN
    Semin Respir Crit Care Med; 2003 Feb; 24(1):121-34. PubMed ID: 16088531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).
    Turner PJ
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):291-3. PubMed ID: 15582303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibiotic resistance--bacteria fight back].
    Tambić Andrasević A
    Acta Med Croatica; 2004; 58(4):245-50. PubMed ID: 15700679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
    Patzer JA; Dzierzanowska D; Turner PJ
    J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia Rodríguez JA; Martin R; Soria G; Zapardiel J;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases.
    Aziz MA; Wright A
    Clin Infect Dis; 2005 Aug; 41 Suppl 4():S258-62. PubMed ID: 16032561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
    Mutnick AH; Rhomberg PR; Sader HS; Jones RN
    J Antimicrob Chemother; 2004 Feb; 53(2):290-6. PubMed ID: 14711839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Community health outreach program of the Chad-Cameroon petroleum development and pipeline project.
    Utzinger J; Wyss K; Moto DD; Tanner M; Singer BH
    Clin Occup Environ Med; 2004 Feb; 4(1):9-26. PubMed ID: 15043361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).
    Jones RN; Deshpande L; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):211-6. PubMed ID: 15246512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibiotic resistance: recommendations from the Advisory Council for Health Research].
    Hoogkamp-Korstanje JA
    Ned Tijdschr Geneeskd; 2001 Jun; 145(25):1192-3. PubMed ID: 11447873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of the 1997 SENTRY Antimicrobial Surveillance Program in Three Brazilian Medical Centers.
    Sader HS; Sampaio JL; Zoccoli C; Jones RN
    Braz J Infect Dis; 1999 Apr; 3(2):63-79. PubMed ID: 11098193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore.
    Hsu LY; Kwa AL; Lye DC; Chlebicki MP; Tan TY; Ling ML; Wong SY; Goh LG
    Singapore Med J; 2008 Oct; 49(10):749-55. PubMed ID: 18946605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.